The Future Of RNA Manufacturing Starts With Raw Material Innovation

As the possibilities of mRNA and oligonucleotide therapeutics grow, drug sponsors are evaluating how best to harness these technologies to treat a broader range of diseases and offer more personalized medicines. One key factor in this pursuit is the ability to ensure a robust, reliable raw material supply chain; sponsors must strategically partner with raw material suppliers to protect the safety and efficacy of their drugs.

Furthermore, as the field evolves, suppliers are exploring how to make raw materials such as capping agents, RNA polymerase, and lipid nanoparticles more efficient and effective. As both experienced and emerging suppliers enter the mRNA and oligonucleotide supply chain, sponsors must balance the safety and reliability of established approaches with the risks inherent in adopting new technologies for greater performance. Download the full article to explore critical due diligence strategies to ensure that raw materials and their suppliers meet the needs of your process.